Negotiations with NHIS on Actemra have been completed

By Lee, Tak-Sun | translator Choi HeeYoung

22.02.25 09:08:43

가나다라 0

The MOHW revised the regulations for severely ill patients, and officially debuted as a COVID-19 drug

Full support is provided without patient's copayment, and additional overseas manufacturers are added

Actemra (Tocilizumab), a treatment for rheumatoid arthritis by JW Pharma, has been officially recognized as a treatment for COVID-19 in Korea. The drug, which has been used in patients with severe COVID-19 for purposes other than permission, will also be covered by health insurance benefits from March.

On the 24th, the MOHW announced that Actemra is preparing to revise the regulations so that benefits can be applied as a treatment for COVID-19.

Earlier, the NHIS negotiated with JW Pharma, a domestic importer and seller, to apply benefits. Through this, it is possible to apply benefits to severely ill patients with COVID-19. According to the revision of the MOHW, medical care benefits are

Lee, Tak-Sun(hooggasi2@dailypharm.com)

If you want to see the full article, please JOIN US (click)